KNSA 8-K 2026-07-28

Kiniksa Pharmaceuticals International, plc (KNSA) 8-K dated 2026-07-28 — accession 0001730430-26-000031. This URL is the filing, not the KNSA hub.

Kiniksa Pharmaceuticals International, plc (KNSA) is a drug manufacturers - specialty & generic company listed on US.

Kiniksa Pharmaceuticals International, plc filed a 8-K on 2026-07-28. Accession 0001730430-26-000031.

Cached items: 2.02, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported KNSA revenue for 2025-12-31 was $677.6M. Net income was $59.0M. Revenue was up 60.1% from 2024-12-31 to 2025-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.

Not investment advice. The KNSA SEC hub lists recent forms. The stock page is the research view.